Objective: To assess the efficacy of combination epirubicine, oxaliplatin and capecitabine (EOX) in unresectable advanced gastric cancer. Patients and Methods: the authors randomly assigned 68 patients with unresectable advanced gastric cancer to receive triplet therapy with EOX between November 2011 and September 2012 at National Cancer Hospital. The end point was response to treatment and overall survival with noncontrolled clinical trial method. Result: The performance status was evaluated by ECOG with PS = 0-1 were 97,2 percent. Percentage of patients with PS=O strongly increase from 23,4 percent up to 70,6 percent. The reduction of triplet tumor markers CEA, CA19-9, CA 72-4 were statistically significant. The overall response rate was 52,9 percent, complete response rate was 8,8 percent and the stable disease was 32,4 percent. There was a statistically significant interaction between treatment dose and response rate witfl OR= 2,86. Overall survival median was 7,67 months. Conclusions: EOX improved the quality of life and gived the new hope for patients with unresectable advanced gastric cancer with acceptable toxicity and favqrable survival.